GS Group and Goldman Sachs & Co. LLC Jointly Report 308-Share Stake in TSVT
Rhea-AI Filing Summary
2seventy bio, Inc. Schedule 13G/A shows The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly report beneficial ownership of 308 shares of the issuer's common stock. The filers state no sole voting or dispositive power and report shared voting power of 133 shares and shared dispositive power of 308 shares. The reported amount represents 0.0% of the class and is described as ownership of 5% or less. The filers certify the securities are held in the ordinary course of business and not for the purpose of changing control. The filing includes a joint filing agreement and identifies GS Group as a parent holding company with Goldman Sachs as a subsidiary broker-dealer and investment adviser.
Positive
- Joint filing agreement included, clarifying reporting responsibilities between GS Group and Goldman Sachs & Co. LLC
- Ownership is 5% or less, reported as 308 shares (0.0% of class), indicating a de minimis stake
- Filers certify holdings are in the ordinary course of business and not intended to influence control
Negative
- None.
Insights
TL;DR: Reported holdings are de minimis—308 shares (0.0%), indicating no material economic or control stake.
The Schedule 13G/A discloses a small, jointly reported position of 308 shares in 2seventy bio. With 0 sole voting/dispositive power and only 133 shared votes, this holding is immaterial to ownership concentration and unlikely to affect capitalization or governance. The filing's certification that the shares are held in the ordinary course and the inclusion of a joint filing agreement confirm routine custody/trading or advisory activity rather than an activist intent. Impact on investors is neutral.
TL;DR: Legal formality of joint Schedule 13G/A; ownership and voting influence are negligible.
The report identifies GS Group and its subsidiary as joint filers and classifies the positions under standard reporting types. The combination of no sole power, shared voting power of 133, and an overall stake of 308 shares (0.0%) indicates no practical governance influence. The explicit certification that holdings are not intended to change or influence control reduces regulatory and activist signaling. This disclosure is routine and non-impactful for board-level or strategic considerations.